GLP1R and type 1 diabetes mellitus: Clinical trials employing liraglutide (human GLP-1 analogue) or exenatide (exendin-4 derivates, animal GLP-1) in addition to intensified insulin regimes in T1D patients did not demonstrate convincing hypoglycemic benefits or describe potential adverse outcomes such as a higher risk of ketoacidosis.